BiotechTube

Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SCLC, Extensive Stage

Conditions

SCLC, Extensive Stage

Trial Timeline

Jul 24, 2023 → Dec 1, 2026

NCT ID
NCT07136285

About Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide

Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide is a phase 1/2 stage product being developed by Genelux for SCLC, Extensive Stage. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07136285. Target conditions include SCLC, Extensive Stage.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07136285Phase 1/2Recruiting

Competing Products

20 competing products in SCLC, Extensive Stage

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
74
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
BBP-398 + osimertinibLianBioPhase 1
25
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
33
YH42946YuhanPhase 1/2
41
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
41
DS-1205c + OsimertinibDaiichi SankyoPhase 1
33
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
77
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
52
gilteritinibAstellas PharmaPhase 1
33
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
naquotinib + midazolamAstellas PharmaPhase 1
33
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
52
ExisulindAstellas PharmaPhase 1/2
41
naquotinibAstellas PharmaPhase 1
33
ASP8273Astellas PharmaPhase 2
52

Other Products from Genelux

olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)Phase 3
69
Olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin or cisplatin + Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC + Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab + DocetaxelPhase 2
44
GL-ONC1Phase 1/2
33
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumabPhase 1/2
33
GL-ONC1Phase 1
25